Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Varsha Gandhi, PhD, on Ibrutinib

Opening Session Panel Discussion

Advertisement

Advertisement




Nov
06
Today In Oncology
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Pediatric Brain Tumors Prognostic AI Model Guides Precision Therapy Choices
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo